Clinical Trial ECOGGIR1010


A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma

Principal Investigator(s)

Bapsi Chak


  • Protocol No. ECOGGIR1010
  • Open Date: 02/28/2013
  • Staging: Phase III
  • Age Group: Adults
  • Scope: National
  • Objective: To determine if trastuzumab increases disease-free survival when combined with trimodality treatment (radiation plus chemotherapy followed by surgery) for patients with HER2-overexpressing esophageal adenocarcinoma
  • Disease Sites: Esophageal
  • Therapies: Chemotherapy - cytotoxic; Correlative; Molecular Targeted Agents / Immunotherapy / Biologics; Radiotherapy; Surgery
  • Drugs: Carboplatin; Herceptin; Paclitaxel; Trastuzumab (Herceptin)
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: 01196390
  • Secondary Protocol No: RTOG-1010